Evaluating drug-drug interaction risk is a crucial part of drug safety evaluation required by drug regulatory authorities. The available services cover the identification of metabolising enzymes, enzyme inhibition and enzyme induction assays, as well as transporter-mediated drug-drug interactions.
Service List
CYP Inhibition
Assess inhibition of major CYP450 isoforms using microsomes, recombinant enzymes, or hepatocytes. We provide high-throughput screening, time-dependent inhibition assays, and detailed kinetic parameters to evaluate DDI risk.
UGT Inhibition
Evaluate inhibition of UGT isoforms (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, UGT2B15) with recombinant enzyme assays. Generate IC50 values to assess potential drug-drug interaction liabilities.
Inhibition of Other Metabolising Enzymes
Investigate inhibition of non-CYP pathways, including SULT, FMO, MAO, NAT, AOX, and CE. Using recombinant enzymes and probe substrates, we deliver reliable IC50 values for less common but clinically relevant mechanisms.
CYP Induction
Characterize induction of CYP1A2, CYP2B6, and CYP3A4 using pooled hepatocytes. We provide both cost-efficient screening assays and regulatory-compliant studies aligned with FDA/EMA guidelines, reporting fold-induction and EC50 values.
UGT Induction
Assess induction of key UGT isoforms, including UGT1A1, UGT1A9, and UGT1A4. Our assays evaluate mRNA expression and enzyme activity endpoints to determine the impact of your compound on glucuronidation pathways.
Transporter Interactions
Identify and characterize transporter-mediated drug-drug interactions for regulatory-relevant transporters (MDR1, BCRP, OATP1B1/1B3, OAT1/2, OCT2) as well as OCT1, MATE1, and MATE2-K. Data supports regulatory submissions and clinical study decisions.
